Ethical use of off-label disease-modifying therapies for multiple sclerosis

BACKGROUND: Off-label disease-modifying therapies (DMTs) for multiple sclerosis (MS) are used in at least 89 countries. There is a need for structured and transparent evidence-based guidelines to support clinical decision-making, pharmaceutical policies and reimbursement decisions for off-label DMTs...

Descripción completa

Detalles Bibliográficos
Autores principales: Laurson-Doube, Joanna, Rijke, Nick, Helme, Anne, Baneke, Peer, Banwell, Brenda, Viswanathan, Shanthi, Hemmer, Bernhard, Yamout, Bassem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Future Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358542/
https://www.ncbi.nlm.nih.gov/pubmed/34304636
http://dx.doi.org/10.1177/13524585211030207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358542/
https://www.ncbi.nlm.nih.gov/pubmed/34304636
http://dx.doi.org/10.1177/13524585211030207

Ejemplares similares